To evaluate the neuroprotective potential of empagliflozin using the Olink Neurodegeneration Panel: A post-hoc analysis of the EMPEROR Program
Abstract
Heart failure is a long-term condition in which the heart cannot pump blood as well as it should. It affects tens of millions of people worldwide and is a leading cause of hospital admission and early death. Many people with heart failure also experience problems with memory and thinking over time. This suggests that heart disease and brain health are closely connected, sometimes called the “heart–brain connection.” Reduced blood flow, long-term inflammation, and changes in body metabolism may slowly damage brain cells, but this process is still poorly understood. Empagliflozin is a medicine currently used to treat heart failure, kidney disease and diabetes (uncontrolled blood sugar). It belongs to a group of drugs called sodium–glucose co-transporter 2 (SGLT2) inhibitors, which lower blood sugar and protect the heart and kidneys. Large clinical trials have already shown that empagliflozin reduces the risk of death and hospitalisation in people with heart failure. However, it is not yet known whether this treatment can also protect the brain from ongoing damage. In this study, we will investigate whether empagliflozin may help reduce injury to brain cells in people with heart failure. We will do this by analyzing measurements of substances in the blood that are released when brain cells are damaged. These substances, often called biomarkers, include proteins linked to nerve injury and diseases such as Alzheimer’s disease. Higher levels of these proteins may reflect ongoing…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.